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Purpose: To study the effect of the concomitant use of brinzolamide and latanoprost on the 
24-hour variation in intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients 
first treated with timolol and latanoprost.
Methods: We studied 30 eyes from 30 POAG patients previously treated with latanoprost 
monotherapy. After a washout of four weeks in both eyes, all patients were treated with 0.5% 
timolol and latanoprost. Three months after the initiation of treatment with timolol and latanoprost, 
the 24-hour IOP variation was measured. Thereafter, all patients were treated with concomitant 1% 
brinzolamide and latanoprost. Three months after changing the therapeutic regimen, the 24-hour 
IOP variation was measured a second time. Latanoprost was administered once a day, and timolol 
and brinzolamide were twice a day. IOP was measured with a noncontact tomometer.
Results: On treatment with brinzolamide and latanoprost, a significant decrease in IOP compared 
to timolol and latanoprost was observed at all time points except at 3 PM and 6 PM. As a group, 
the patients had a significantly lower diurnal mean IOP and nocturnal mean IOP during treatment 
with brinzolamide and latanoprost than with timolol and latanoprost.
Conclusions: Treatment of POAG with a combination of brinzolamide and latanoprost 
demonstrated improved hypotensive effects compared with timolol and latanoprost during a 
24-hour period.
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Introduction
The most important risk factor in glaucoma is poorly controlled ocular hypertension.1 
Therefore, a therapy that lowers intraocular pressure (IOP) is the most reliable approach 
for glaucoma.
Timolol, a relatively nonselective β-blocker, lowers IOP by suppressing the 
production of aqueous humor and is considered to be among the most effective 
glaucoma medications developed over the past 20 years. However, it is likely that 
timolol may cause adverse reactions in the cardiovascular and respiratory systems,2,3 
and hence, a carefully obtained medical history is necessary to identify any predisposing 
condition.4
Prostaglandin F2α analogs (PGA) are a class of IOP-lowering medications that 
reduce IOP by increasing the aqueous humor outflow rate via the uveoscleral route.5 The 
PGA latanoprost has a favorable IOP-lowering effect and causes no serious systemic 
adverse reactions; consequently, it has been widely used as a first-line glaucoma Clinical Ophthalmology 2009:3 494
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medication.6 However, PGA has several local side effects 
such as iris pigmentation,7 poliosis,8 eyelid pigmentation,9 etc. 
Occasionally, patients cannot attain their target IOP and either 
switch to another PGA and/or require adjunctive therapy.10 
Unfixed8 or fixed combinations11,12 of latanoprost and timolol 
have been demonstrated to effectively lower IOP.
Brinzolamide is a more recently developed carbonic 
anhydrase inhibitor.13–15 The effects of coadministration of 
brinzolamide with latanoprost have been explored in few 
studies.16–20 Brinzolamide lowers IOP by suppressing the 
production of aqueous humor. Indeed, brinzolamide mono-
therapy appears to have a weaker IOP-lowering effect than 
β-blocker monotherapy;17 however, brinzolamide is expected 
to exert a further IOP-lowering effect when added to a PGA, 
like other carbonic anhydrase inhibitors.21,22 Nakamoto and 
Yasuda23 reported that when single-agent latanoprost was 
compared to concomitant treatment with brinzolamide 
and latanoprost, the combination therapy exerted a greater 
nocturnal IOP-lowering effect. Additionally, it has been 
reported that the concomitant use of PGA 0.004% travoprost 
and 0.1% brinzolamide is superior in its IOP-lowering effect 
to the fixed combination (Xalacom; Pfizer, New York, NY, 
USA) of 0.005% latanoprost and 0.5% timolol.22
In this single-arm study, patients with primary open-angle 
glaucoma (POAG) were coadministered timolol and latano-
prost for three months, after which the therapy was changed 
to brinzolamide and latanoprost in order to investigate 
potential changes in circadian IOP variation. In addition, 
the cardiovascular safety of these two combination regimens 
was also investigated.
Patients and methods
Inclusion and exclusion criteria
Patients with POAG receiving outpatient care at the 
Department of Ophthalmology, Ogachi Central Hospital, 
Akita, Japan, were enrolled. The study was carried out in 
accordance with the World Medical Association’s Declaration 
of Helsinki and was approved by the ethical review board at 
Ogachi Central Hospital.
Patients were selected from those who had latanoprost 
monotherapy for over three months. Patients were required to 
provide written informed consent; have a typical glaucomatous 
optic disc finding with a corresponding visual field defect in 
both eyes; and lack any eye, nasal sinus, or systemic disease 
affecting the optic nerve. Additional exclusion criteria included 
heart disease, respiratory disease, past history of renal disease, 
past history of serious corneal lesion or uveitis, past history 
of intraocular surgery or laser treatment, systemic use of a 
carbonic anhydrase inhibitor or β-blocker, corneal endothelial 
cell count of less than 1,500 cells/mm2, and ineligibility to 
participate in this study as judged by the investigators. Ocular 
hypertension of greater than 25 mmHg while using latanoprost 
monotherapy was also excluded from this study in order to 
avoid the risk of further elevation of IOP.
Study design
Patients had a four-week washout period, in which they 
discontinued latanoprost use. Patients then topically applied 
0.5% timolol to both eyes twice daily (8 AM and 8 PM) and 
latanoprost once daily (8 PM). Patients were instructed to use 
forced eyelid closure for three minutes, and keep a time interval 
of five minutes between topical applications when applying 
the drugs at 8 PM. All patients visited the hospital every 
four weeks. A questionnaire asking about current use of eye 
drops was distributed to all patients at the time of their regular 
clinical visits, and their adherence to medication was evalu-
ated. Three months after the start of treatment, the patients 
were hospitalized, during which their 24-hour circadian 
IOP variation was measured as follows: IOP was measured 
three times at each time point in the sitting position with a 
noncontact tonometer (P ULSAIR 2000; Keeler Co, Windsor, 
England) in three-hour intervals for a total of eight times a day 
(6 AM, 9 AM, 12 PM, 3 PM, 6 PM, 9 PM, 12 AM, 3 AM). 
At night, patients were awakened and allowed to relax for 10 
minutes, and then IOP was measured with the patient sitting 
on the bed. According to a previous report,24 measurement was 
calculated three times and averaged if the difference in IOP 
measurement was 3 mmHg or less. When the difference was 
greater than 3 mmHg, the IOP was measured until the differ-
ence in three consecutive values was 3 mmHg or less.
Immediately following this series of measurements, 
1%  brinzolamide  was  substituted  for  timolol,  and 
co-administration with latanoprost was continued for three 
months. Brinzolamide was applied to both eyes twice daily 
(8 AM and 8 PM) and latanoprost once daily (8 PM). As before, 
the patients were instructed to use forced eyelid closure for three 
minutes, along with a five-minute time interval between topical 
applications when applying the drugs at 8 PM. After three 
months of treatment, the patients were hospitalized a second 
time, during which their circadian IOP variation was measured 
again. Blood pressure and pulse rate were measured in triplicate 
between 9 AM and 10 AM on each hospitalization day.
Statistical analysis
From IOP measurements during hospitalization, the 
following outcomes were calculated: (1) 24-hour mean IOP Clinical Ophthalmology 2009:3 495
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(mean value of IOP at all time points), (2) diurnal mean 
IOP (mean value of IOP at 9 AM, 12 PM, and 3 PM), and 
(3) nocturnal IOP (mean value of IOP at 9 PM, 12 AM, and 
3 AM). Percent reduction in IOP was calculated by using 
the following formula:
  Percent reduction in IOP = [(latanoprost + timolol IOP 
  – latanoprost + brinzolamide IOP)/latanoprost  
  + timolol IOP] × 100
Systolic blood pressure, diastolic blood pressure, mean 
blood pressure, and pulse rate were compared before and 
after the transition from timolol to brinzolamide.
Statistical analyses using the right eye of each patient 
were conducted using two-sided paired t-test with a signifi-
cance level of 5%.
Glaucoma criteria
Glaucoma diagnosis was based on optic disc appearance, 
including cup-to-disc ratio; rim width; nerve fiber layer defect; 
the results of the Humphrey Field Analyzer examination; and 
clinical records from screening and definitive examinations. 
The criteria for glaucoma diagnosis were based on the criteria 
of previous population studies,25 described in Table 1. First, 
when the vertical cup-to-disc ratio of the optic nerve head 
was 0.7 or more; or the rim width at the superior portion (the 
11 to 1 o’clock position) or inferior portion (the 5 to 7 o’clock 
position) was 0.1 or less of disc diameter; or the difference 
in the vertical cup-to-disc ratio was 0.2 or more between 
both eyes; or a nerve fiber layer defect was found – and the 
Hemifield-based visual field abnormality was compatible with 
optic disc appearance or nerve fiber layer defect – the eye 
was diagnosed with glaucoma (Category 1). Next, when the 
vertical cup-to-disc ratio was 0.9 or more; or the rim width at 
the superior portion (the 11 to 1 o’clock position) or inferior 
portion (the 5 to 7 o’clock position) 0.05 or less; or the differ-
ence in the vertical cup-to-disc ratio was 0.3 or more between 
both eyes – when the visual field test result was not reliable or 
available – a diagnosis was obtained of glaucoma (Category 2). 
When the eye with the cup-to-disc ratio was 0.7 or more but 
less than 0.9; or the rim width at the superior portion (the 11 
to 1 o’clock position) or inferior portion (the 5 to 7 o’clock 
position) was 0.1 or less but more than 0.05 of the disc diameter; 
or the difference of the vertical cup-to-disc ratio was 0.2 or 
more but less than 0.3 between both eyes; or a nerve fiber 
layer defect was found – and the visual field test was not reli-
able or available or did not show compatible Hemifield-based 
defect – the eye was diagnosed as being glaucoma suspect 
(Glaucoma suspect). In the definitive diagnosis, anomalous 
discs, including tilted discs, were carefully excluded.
Results
Thirty patients were enrolled in this study. Fifty percent 
(n = 15) of the patients were male. The mean age of the total 
patient population was 70.2 ± 10.2 years old. No patients 
discontinued treatment or withdrew from the study. Prior 
to enrollment, all participants were treated with 0.005% 
latanoprost monotherapy, which was topically applied 
to both eyes once daily at night for 5.5 ± 2.0 months; it 
produced 20%–33% reduction in IOP (the mean IOP 
range was 16.8 ± 3.2 mmHg). The minimum untreated 
IOP was 17 mmHg, and the average untreated IOP was 
18.9 ± 5.6 mmHg. The visual field mean deviation (MD) 
at enrollment was −4.2 ± 3.2 dB on the Humphrey Field 
Analyzer, Center 30–2 Program.
IOP was analyzed using the data from the right eye 
of the enrolled patients. The comparison of mean IOP 
Table 1 The criteria for primary open-angle glaucoma diagnosis
Category 1





rior portion (11–1 hours) or the inferior portion (5–7 hours) is 0.05 or less of the disc diameter, or the difference of the vertical cup-to-disc ratio is 
0.3 or more between both eyes
Glaucoma suspect
When the cup-to-disc ratio of the optic nerve head is 0.7 or more but less than 0.9, or the rim width at the superior portion (11–1 hours) or the 
inferior portion (5–7 hours) is 0.1 or less but more than 0.05 of the disc diameter, or the difference of the vertical cup-to-disc ratio is 0.2 or more 
but less than 0.3 between both eyes, or the nerve fiber layer defect is found, and the visual field test is not reliable or available or does not show 
hemifield-based compatible defect, the eye is diagnosed with suspected glaucomaClinical Ophthalmology 2009:3 496
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between treatment regimens at each time point showed that 
a significant IOP reduction was observed after the transition 
to brinzolamide and latanoprost at all time points except at 
3 PM and 6 PM (Figure 1, P  0.01). The 24-hour mean 
IOP with timolol and latanoprost was 12.6 ± 2.4 mmHg 
compared to 11.9 ± 2.5 mmHg after the change in treatment 
to brinzolamide and latanoprost. This represents a 
statistically significant difference (Figure 2, P  0.01) that 
translated into a 5.8% ± 1.5% reduction in IOP. Diurnal 
mean IOP was 12.6 ± 2.3 mmHg before the transition, and 
11.8 ± 2.3 mmHg after the transition (Figure 2,  P  0.05) for 
a 7.3% ± 1.9% reduction in IOP. The nocturnal mean IOP was 
13.1 ± 3.4 mmHg before the transition and 11.7 ± 3.1 mmHg 
after the transition, showing a statistically significant 
reduction in IOP (Figure 2, P  0.001) of 9.6% ± 1.9%. The 
maximum mean IOP was 15.0 ± 3.9 mmHg with timolol and 
latanoprost therapy and 14.1 ± 4.2 mmHg with brinzolamide 
and latanoprost therapy, showing a significant reduction in 
IOP of 6.1% ± 2.3% (Figure 3, P  0.05). The minimum 
mean IOP was 10.5 ± 1.9 mmHg before the transition and 
10.2 ± 1.7 mmHg after changing the regimen, showing no 
significant difference between the two regimens (Figure 3). 
The IOP range was 4.3 ± 2.4 mmHg before the change 
from timolol to brinzolamide and 3.9 ± 2.5 mmHg after the 
transition, showing no statistically significant difference 
(Figure 3).
Based on the questionnaire on the use of eye drops, 
patient adherence was calculated to be least 90% in all cases 
for each medication.
No statistically significant difference in systolic blood 
pressure, diastolic blood pressure, or mean blood pressure 
was observed between the treatment regimens (Table 2). 
The pulse rate was significantly higher after the transition 
to brinzolamide and latanoprost therapy (65.7 ± 5.7 vs 
72.9 ± 6.7 beats/minute, P  0.05; Table 2).
Adverse events observed during the study are presented 
in Table 3. Mild conjunctival hyperemia (one patient) 
and corneal epithelial disorder (one patient) were observed 
while taking timolol and latanoprost, but these symptoms 
disappeared after transitioning to brinzolamide and 
latanoprost. Taste perversion (one patient) was observed 
after the transition to brinzolamide and latanoprost, but it was 
present only transiently and required no treatment.
Discussion
Concomitant treatment with timolol and latanoprost was 
conducted for three months in patients with open-angle 






















Timolol + Latanoprost Brinzolamide + Latanoprost
*** * * ** ***  **
6 AM 9 AM 3 AM 12 AM 9 PM 6 PM 12 PM
Figure 1 Comparison of mean intraocular pressure levels (millimeters of mercury) for timolol and latanoprost versus brinzolamide and latanoprost across a 24-hour time 
period (n = 30).
Notes: *P  0.05, **P  0.01, ***P  0.001, mean ± SE (paired t-test).
Abbreviations: IOP, intraocular pressure; SE, standard error.Clinical Ophthalmology 2009:3 497
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Timolol + Latanoprost Brinzolamide + Latanoprost
*** * **
24-h mean Nocturnal
Figure 2 Comparison of 24-hour mean IOP (averaged across all time points), diurnal mean IOP (9 AM, 12 PM, and 3 PM), and nocturnal mean IOP (9 PM, 12 AM, and 3 AM) 
for timolol and latanoprost versus brinzolamide and latanoprost (n = 30).
Notes: *P  0.05, **P  0.01, ***P  0.001, mean ± SE (paired t-test).






















Timolol + Latanoprost Brinzolamide + Latanoprost
*
Mean maximum IOP  Mean minimum IOP  Range
Figure 3 Comparison of mean maximum IOP, mean minimum IOP, and mean IOP range for eyes receiving timolol and latanoprost versus brinzolamide and latanoprost (n = 30).
Notes: *P  0.05, mean ± SE (paired t-test).
Abbreviations: IOP, intraocular pressure; SE, standard error.Clinical Ophthalmology 2009:3 498
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and latanoprost for three months, in a topical medication 
transition study. When treatment was changed from timolol 
and latanoprost to brinzolamide and latanoprost, the most 
significant IOP-lowering effect was documented at night. 
The mean IOP difference was also statistically significant. 
These results may indicate that brinzolamide provides a 
more sustained IOP-lowering effect than timolol through-
out a 24-hour period when added to latanoprost. Since 
lowering IOP reduces the risk of glaucoma onset and 
progression, it is clinically meaningful for individual patients. 
In contrast, timolol lowers office-hour IOP, but it has little 
IOP-lowering effect at night. These observations are consistent 
with a previous report showing different IOP-lowering effect 
of brinzolamide and timolol used as monotherapy26 or add-on 
therapy to latanoprost.27
Control of nocturnal IOP is important for progression 
of visual field defects in glaucoma.28 However, the precise 
mechanism of IOP regulation by brinzolamide during 
the nocturnal period is not fully understood. Although 
brinzolamide caused a smaller reduction in aqueous 
humor formation during the nocturnal period than dur-
ing the diurnal period,15 brinzolamide significantly reduced 
the nocturnal IOP.28 The reason for the present difference 
in nocturnal IOP-lowering effect between the two treat-
ment regimens can be explained by the fact that timolol 
does not produce a nocturnal IOP-lowering effect.14,29 
Although brinzolamide produced superior IOP-lowering 
results compared to timolol in this study, we must discuss 
the following limitation of the present study design. The 
patients were not randomized into treatment with either 
brinzolamide and latanoprost or timolol and latanoprost. 
Thus, the treatment sequence or underlying changes in 
the disease over time could have affected the results of 
this study.
In recent years, it has been suggested that glaucomatous 
optic neuropathy may be caused by a reduction in blood 
flow in the optic disc because of nocturnal hypotension 
and heart rate decrease.30 Hayreh and colleagues31 reported 
that when a β-blocker was topically applied to glaucoma 
patients, nocturnal blood pressure and heart rate were 
reduced, thereby deteriorating the visual field. For this 
reason, it may be desirable to use drugs that have minimal 
effects on the cardiovascular system of glaucoma patients. 
The merits of brinzolamide include fewer ocular adverse 
events32 and no serious systemic adverse reactions.23 
A previous study has shown that, in contrast to timolol, 
brinzolamide does not exert any suppressive effect on 
heart rate.33 Confocal laser Doppler flowmetry shows the 
positive blood flow effect of brinzolamide, which increases 
retinal oxygen saturation in patients with glaucoma.34 In the 
current investigation as well, treatment with brinzolamide 
and latanoprost produced no reduction in heart rate; rather, 
the mean pulse rate during timolol therapy was decreased 
compared to brinzolamide. Several population-based 
epidemiological studies35 have shown that ocular perfusion 
pressure (OPP) is a significant risk factor associated with 
glaucoma incidence. OPP is calculated as the following 
formula:
OPP = [mean BP × (2/3) – IOP]
In the present study, mean blood pressure, which is 
directly related to OPP, was similar in the two treatment 
regimens. However, timolol and latanoprost is considered to 
induce an increase in OPP because of concomitant significant 
reduction in IOP.
All three adverse reactions observed in the current 
study were mild and did not result in discontinuation of 
treatment. The frequency of ocular and systemic adverse 
reactions in this study was similar to those in previous 
reports.12,17,19,36
Although it is an applanation tonometer is commonly 
used, we measured the IOP with a noncontact tonometer 
in our study because of the inconvenience of our 
accommodation: the setting of a slit-lamp attached to 
Table 2 Comparison of blood pressure and pulse rate before and 
after changing treatment




Systolic 128.5 ± 15.6 130.1 ± 14.7
Diastolic   78.1 ± 7.9   79.1 ± 12.6
Mean   94.5 ± 13.4   95.1 ± 11.9
Pulse rate (beat/min)   65.7 ± 5.7   72.9 ± 6.7*
Note: *P  0.05 (paired t-test).
Table 3 Adverse events observed during the study





Conjunctival hyperemia 1 0
Corneal epithelial damage 1 0
Systemic adverse reactions
Taste perversion 0 1Clinical Ophthalmology 2009:3 499
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applanation tonometer was located far from the bedside of 
our patients. We were afraid to allow the patients to walk 
for a distance, especially at midnight, because it is known 
that the circadian clock is responsible for the temporal 
organization of several functions, such as heart rate; body 
temperature; and hormonal release.37 Therefore, in the 
present study, we went to the patient bedside to measure 
the IOP by ourselves.
Conclusions
When taken together, the combination of brinzolamide and 
latanoprost demonstrated an improved hypotensive effect 
in open-angle glaucoma patients compared to timolol and 
latanoprost during a 24-hour period.
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